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A B S T R A C T
The ubiquitin–proteasome system (UPS) is a catalytic machinery that targets numerous cellular proteins
for degradation, thus being essential to control a wide range of basic cellular processes and cell survival.
Degradation of intracellular proteins via the UPS is a tightly regulated process initiated by tagging a target
protein with a specific ubiquitin chain. Neurons are particularly vulnerable to any change in protein
composition, and therefore the UPS is a key regulator of neuronal physiology. Alterations in UPS activity
may induce pathological responses, ultimately leading to neuronal cell death. Brain ischemia triggers a
complex series of biochemical and molecular mechanisms, such as an inflammatory response, an
exacerbated production of misfolded and oxidized proteins, due to oxidative stress, and the breakdown of
cellular integrity mainly mediated by excitotoxic glutamatergic signaling. Brain ischemia also damages
protein degradation pathways which, together with the overproduction of damaged proteins and
consequent upregulation of ubiquitin-conjugated proteins, contribute to the accumulation of ubiquitin-
containing proteinaceous deposits. Despite recent advances, the factors leading to deposition of such
aggregates after cerebral ischemic injury remain poorly understood. This review discusses the current
knowledge on the role of the UPS in brain function and the molecular mechanisms contributing to UPS
dysfunction in brain ischemia with consequent accumulation of ubiquitin-containing proteins. Chemical
inhibitors of the proteasome and small molecule inhibitors of deubiquitinating enzymes, which promote
the degradation of proteins by the proteasome, were both shown to provide neuroprotection in brain
ischemia, and this apparent contradiction is also discussed in this review.
 2013 Elsevier Ltd. All rights reserved.
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Brain ischemia is a leading cause of death and disability
worldwide, resulting from a reduction in the blood flow to the
brain. This leads to a deprivation of oxygen and glucose, and cell
death is the fatal end caused by the reduction of the fuels available
for the metabolism of the cells. Brain ischemia may be caused by
cardiac arrest (global ischemia, affecting the entire brain) or by
ischemic stroke (focal ischemia, which targets a specific brain
region).
Ischemic stroke occurs as a result of the occlusion of a blood
vessel supplying blood to the brain by a thrombus or an embolus
(Doyle et al., 2008; Roger et al., 2012). In this condition, the region
of the brain that is most damaged, the ischemic core, fully depends
on oxygen and glucose provided by the affected blood vessel, while
the penumbra region, the area surrounding the infarcted core, is
not as compromised due to a limited supply of components
required for the metabolism derived from the collateral circula-
tion. Glucose is the main substrate for cerebral energy production
(Hofmeijer and van Putten, 2012) and during stroke the oxygen
carried by the blood is much less than that required for complete
oxidation of its content of glucose. Under these conditions,
glycolysis may persist after oxygen has been depleted, but the
reduction of oxidative metabolism of glucose leads to decreased
ATP levels, while ADP and AMP levels increase (Hertz, 2008),
causing a disruption of ionic homeostasis (Hansen, 1985), opening
of anion channels (Kimelberg and Mongin, 1998), plasma
membrane depolarization (Lipton, 1999), release of glutamate
through astrocytic hemichannels (Ye et al., 2003) and down-
regulation of glutamate transporters (Harvey et al., 2011). The
impairment of glutamate transporters, in addition to their
operation in the reverse mode, leads to an accumulation of
glutamate in the extracellular space (Grewer et al., 2008) and a
consequent overactivation of postsynaptic glutamate receptors.
Under these conditions, necrotic cell death occurs at the core
region, while in the penumbra region the availability of ATP allows
a delayed cell death by apoptosis (Broughton et al., 2009).
The hippocampus is particularly vulnerable to brain ischemia,
but distinct responses are typically observed in the different
hippocampal subregions. The CA1 region is highly sensitive totransient ischemia followed by reperfusion, but this neuronal
population die far later after ischemic insult, a process referred to
as delayed neuronal death (Kirino, 1982; Pulsinelli et al., 1982a).
This is a unique type of cell death that progresses despite complete
recovery of metabolic parameters, such as regional blood flow,
glucose metabolism and tissue ATP content (Kirino, 1982;
Pulsinelli et al., 1982b; Mies et al., 1990), but the molecular
mechanisms involved are yet to be clearly understood.
1.1. Role of glutamate
During stroke, membrane depolarization due to ATP breakdown
leads to an increase in the release of glutamate, and the lack of
energy blocks the reuptake of the excitatory amino acids at the
synapse, leading to an extracellular accumulation of glutamate
(Rossi et al., 2000; Grewer et al., 2008). The reversal of the
glutamate transporters under these conditions (Rossi et al., 2000;
Grewer et al., 2008) further contributes to the extracellular
accumulation of glutamate, with a consequent toxic overactivation
of postsynaptic glutamate receptors (excitotoxicity) (Olney, 1969;
Simon et al., 1984; Choi et al., 1987; Ferreira et al., 1996, 1998;
Martel et al., 2012). Upon oxygen and glucose deprivation (OGD), a
well established in vitro model of global ischemia, glutamate is
massively released by neurons, and the resulting increase in the
intracellular Ca2+ concentration ([Ca2+]i) (Goldberg and Choi, 1993)
causes a delayed neuronal cell death (calcium overload hypothesis)
(Manev et al., 1989). Ca2+ uptake and neuronal cell death can be
prevented by the NMDA (N-methyl-D-aspartate) receptor
(NMDAR) antagonist D-aminophosphonovalerate (APV) (Goldberg
and Choi, 1993). In addition, the volume of microinfarcts induced
by occlusions of individual penetrating arterioles or venules in the
rat brain cortex could be reduced by administrating memantine
30–45 min after the occlusion, ameliorating perceptual deficits
(Shih et al., 2013). These data indicate that NMDAR, characterized
by their high Ca2+ permeability, are the link between glutamate,
Ca2+ and neuronal cell death. On the other hand, it was shown that
blocking NMDAR with MK-801 decreases the density of healthy
cells in the dentate gyrus (Gould et al., 1994), indicating that a
moderate flow of Ca2+ ions through NMDAR is beneficial for
neurons, while Ca2+ overload, linked with an excessive NMDAR
M.V. Caldeira et al. / Progress in Neurobiology 112 (2014) 50–6952activation, is deleterious (NMDAR paradox) (Hardingham and
Bading, 2003).
Not all NMDAR contribute to neuronal cell death in excito-
toxicity, since the synaptic and extrasynaptic receptor populations
are differentially coupled to the activation of intracellular signaling
mechanisms: the latter receptors mediate the influx of calcium
ions leading to mitochondrial injury (Stanika et al., 2009),
activation of pro-apoptotic genes (Leveille et al., 2010), cleavage
of fodrin and the sodium–calcium exchanger type-3 (NCX3) by
calpains (Xu et al., 2009a), and cell death (Hardingham et al., 2002).
On the other hand, activation of synaptic NMDAR is not coupled to
hippocampal neuron damage (Hardingham et al., 2002), but rather
promotes resistance to oxidative insults and prevents accumula-
tion of reactive oxygen species in cortical neurons (Papadia et al.,
2008) (Fig. 1). Furthermore, synaptic NMDA receptors induce
genomic alterations that render neurons more resistant to
apoptosis and oxidative insults (Hardingham et al., 2002; Leveille
et al., 2010; Kaufman et al., 2012; Karpova et al., 2013). However,
the relative role of synaptic and extrasynaptic NMDAR in
excitotoxic cell death needs further investigation, considering
the conflicting results showing neurotoxicity induced by synaptic
NMDAR (Papouin et al., 2012) and the evidence pointing to a role
for these receptors in hypoxic excitotoxic death (Wroge et al.,
2012).
In addition to the role played by NMDAR in neuronal death in
brain ischemia, AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole
proprionic acid) receptor (AMPAR) activity was also shown toFig. 1. Activation of ionotropic glutamate receptors and downstream responses in brain i
mechanisms in brain ischemia induces glutamate spillover from the synapse which 
associated with the internalization of GluA2-containing AMPAR and synaptic deliver
contribute to the increase in [Ca2+]i (Tanaka et al., 2000; Liu et al., 2006). The [Ca
2+]i over
contributes to cell death (Araujo et al., 2004; Sanchez-Gomez et al., 2011). Calcium in
transcription of anti-apoptotic genes and genes involved in antioxidant defenses (Hardin
contrast, the excessive activation of extrasynaptic NMDAR induces signaling pathways pr
to excitotoxic cell death (Stanika et al., 2009; Leveille et al., 2010; Kaufman et al., 201
mediated cleavage of Myocyte enhancer factor 2 (MEF2), glutamic acid decarboxylase (GA
2012).mediate ischemic stroke damage in hippocampal CA1 pyramidal
neurons (Soundarapandian et al., 2005). Exposure of hippocampal
neurons to a brief period of OGD promotes a redistribution of
AMPAR at the synapse, with internalization of synaptic GluA2-
containing AMPAR and synaptic delivery of AMPAR lacking GluA2
subunits, which are permeable to calcium and zinc (Liu et al.,
2006). In fact, activation of AMPAR was also shown to induce
calpain activation (Araujo et al., 2004), and AMPAR antagonists
provided neuroprotection in a model of in vivo ischemia (Shear-
down et al., 1990; Noh et al., 2005). Taken together, these data
indicate that NMDAR may act together with AMPAR to induce
neuronal demise under excitotoxic conditions.
1.2. Intracellular calcium overload
The perfect gear that regulates Ca2+ efflux, intracellular Ca2+
buffering and intracellular Ca2+ storage is a neuronal feature that
maintains a low intracellular calcium concentration ([Ca2+]i) when
compared with the extracellular space (Sattler and Tymianski,
2000). Following ischemia, the [Ca2+]i can reach mM levels due to
the breakdown of these mechanisms and the intracellular calcium
overload is linked with overactivation of enzymes such as
proteases, phospholipases and endonucleases, with the resulting
breakdown of proteins, lipids and nucleic acids, and consequent
neuronal death (Coyle and Puttfarcken, 1993; Lee et al., 1999).
Calpains are a group of Ca2+-dependent proteases very well
characterized for their role in neurodegeneration. The excessiveschemia. The increased release of glutamate and the inhibition of glutamate uptake
overactivate iGluR. The downregulation of GluA2 mRNA and protein expression,
y of Ca2+ permeable-AMPAR (lacking GluA2) observed in post-ischemic neurons
load increases calpain activity with consequent cleavage of several proteins, which
flux through synaptic NMDAR induces signaling pathways which upregulate the
gham et al., 2002; Leveille et al., 2010; Kaufman et al., 2012; Karpova et al., 2013). In
omoting transcription of pro-apoptotic genes and mitochondrial injury, contributing
2; Wroge et al., 2012). Moreover, extrasynaptic NMDAR activity induces calpain-
D65/67), Fodrin, NCX3, and STEP (Xu et al., 2009a,b; Monnerie et al., 2010; Wei et al.,
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ischemia and in excitotoxic conditions (Camins et al., 2006; Bevers
and Neumar, 2008) leads to the cleavage of plasma membrane
proteins (Lu et al., 2000; Neumar et al., 2001; Rong et al., 2001;
Yuen et al., 2007; Gomes et al., 2012), synaptic vesicle proteins
(Gomes et al., 2011; Lobo et al., 2011), transporters (Bano et al.,
2005; Pottorf et al., 2006), mitochondrial proteins (Takano et al.,
2005) and many other substrates (Bevers and Neumar, 2008).
Lipases are also activated by calcium, further increasing the
production of free radical species (Farooqui and Horrocks, 1994).
The neuronal isoform of nitric oxide synthase (NOS) is also
activated by Ca2+ and ischemia-associated NO overproduction
perturbs ATP synthesis and induces the release of proteins
involved in cell death (Heales et al., 1999).
Besides the glutamate receptor-induced [Ca2+]i overload (see
above), other channels have been proposed to mediate Ca2+ influx
under excitotoxic conditions. The activation of transient receptor
potential melastatin (TRPM) channels, primarily the Ca2+-perme-
able TRPM2 (Lipski et al., 2006; Jia et al., 2011) and TRPM7
channels (Aarts et al., 2003; Sun et al., 2009), has been associated to
oxidative stress, in addition to anoxic and ischemic cell death.
Another key event during stroke is acidosis, caused by the decrease
in the supply of oxygen to the brain, which leads to calcium influx,
and failure of oxidative phosphorylation, with an increase in
lactate production and the switch to glycolytic metabolism, with
the final decrease in tissue pH (Xiong et al., 2004; Gu et al., 2010).
1.3. Endoplasmic reticulum (ER) stress in brain ischemia
Electron microscopy analysis of the ER and Golgi morphology
showed significant alterations following brain ischemia and
reperfusion, from ‘flattened pancake’ to ‘rounded vesicles’ (Petito
and Pulsinelli, 1984). From the functional point of view, brain
ischemia was shown to impair the sarcoplasmic/endoplasmic
reticulum Ca2+ ATPase, which is responsible for the accumulation
of Ca2+ into the ER (Kohno et al., 1997; Parsons et al., 1997, 1999).
The resulting depletion of Ca2+ in this compartment is known to
induce ER stress (e.g. Nakagawa et al., 2000). Pretreament with a
NO synthase inhibitor significantly reduced the depletion of Ca2+
from the ER in gerbils subjected to transient global cerebral
ischemia, suggesting that the increase in NO production during the
early reperfusion period contributes to the loss in the Ca2+
buffering capacity of the ER (Kohno et al., 1997). Oxidative damage
of the ER during the reperfusion period is also likely to contribute
to the ER stress due to modifications induced in ER proteins
(Hayashi et al., 2003).
Under mild ER stress conditions the cells develop a protective
mechanism, named unfolded protein response (UPR), which is
mediated by induction of molecular chaperones in the ER,
downregulation of translation activity and enhancement of ER-
associated degradation pathways (ERAD). However, more aggres-
sive conditions upregulate the expression of proaptoptotic factors,
including CHOP (C/EBP homologues protein)/GADD153, a member
of the C/EBP family of transcription factors, and caspase-12,
leading to cell death (Feng et al., 2001; DeGracia and Montie, 2004;
Paschen and Mengesdorf, 2005; Boyce and Yuan, 2006).
Inhibition of translation in response to ER stress avoids the
synthesis of proteins that could not be properly folded and,
therefore, is thought to be protective. Translation inhibition in
transient cerebral ischemia correlates with the selective vulnera-
bility of post-ischemic neurons, and may be partly due to a
transient activation of PKR-like ER kinase (PERK). This kinase
phosphorylates the eIF2a (eukaryotic initiation factor 2a) thereby
inhibiting the initiation step of protein synthesis (Kumar et al.,
2001, 2003; Hayashi et al., 2003, 2004; Paschen et al., 2003; Nakka
et al., 2010). However, additional mechanisms may also contributeto the inhibition of protein synthesis after transient brain ischemia
(for more detailed discussion see: DeGracia and Montie, 2004;
DeGracia et al., 2008). mRNAs whose translation is normally
blocked by 50 upstream open-reading frames can still be translated
in the presence of the phosphorylated form of eIF2a (eukaryotic
initiation factor 2a) and this may explain the synthesis of specific
proteins in UPR. The mRNA coding for ATF4 (activating transcrip-
tion factor 4) is translated by this mechanism (Harding et al., 2000),
and the ATF4 transcription factor is known to contribute to chop
mRNA transcription (Ma et al., 2002). An upregulation of the chop
mRNA is a characteristic feature of ER stress and UPR activation,
and was observed in the striatum and hippocampus after transient
bilateral occlusion of common carotid arteries (Tajiri et al., 2004),
as well as in other models of ischemia and reperfusion (Paschen
et al., 1998, 2003; Roberts et al., 2007; Nakka et al., 2010; Osada
et al., 2010). Hippocampal neurons from CHOP/mice exhibited a
significantly lower rate of cell death, when compared with wild-
type animals, indicating that transient ischemia-induced cell death
is mediated by CHOP induction (Tajiri et al., 2004).
Caspase-12 is an ER protease typically activated under ER stress
conditions, and early studies showed a role for this caspase in ER-
stress induced cell death (e.g. Nakagawa et al., 2000). Caspase-12
activation was detected in the ischemic brain at 5 h of reperfusion
after occlusion of the middle cerebral artery (MCAO), which was
accompanied by an increase in caspase-12 protein levels (Shibata
et al., 2003; Nakka et al., 2010). An upregulation of caspase-12
mRNA and protein was also found in the striatum and cerebral
cortex after permanent MCAO in rats (Mouw et al., 2003).
However, the role of this protease in neuronal demise in the
ischemic brain remains to be determined. In fact, it was proposed
that caspase-12 acts mainly as a dominant negative in the
regulation of caspase-1 activity and the main role of the proteolytic
activity of caspase-12 may be in the processing of the protease
(Roy et al., 2008).
A distinct mechanism involved in the alteration of transcription
activity during the UPR is mediated by activation of the
endonuclease IRE1, which processes the mRNA for XBP1 (X-box
binding protein 1) (Yoshida et al., 1998; Calfon et al., 2002). These
mRNAs are translated in a processed XBP1 protein (XBP1proc)
which is translocated to the nucleus, serving as a transcription
factor that induces the expression of ER genes, such as grp78 and
grp94 (Calfon et al., 2002). Although the xbp1 mRNA was found to
be processed early after reperfusion following global and focal
ischemia, a delayed increase in XBP1proc was only observed in the
former conditions (Paschen et al., 2003). The blockade of
translation after transient cerebral ischemia may prevent de novo
synthesis of XBP1proc and the downstream effects on gene
expression.
The unfolded proteins accumulated in the ER bind glucose-
regulated protein 78 (GRP78), an important sensor of the UPR,
leading to the dissociation of binding partners that act as
transcription factors. These proteins translocate to the nucleus,
where they induce the expression of genes coding for molecular
chaperones and folding enzymes, including GRP78 itself, HERP
(homocysteine-inducible, ER-stress inducible protein), GRP94,
calnexin and PDI (protein disulphide isomerase) (Kokame et al.,
2000; Kokame et al., 2001). An increase in the expression of the
grp94, grp78, herp, calnexin and pdi genes was observed after
transient ischemia using different models (Aoki et al., 2001;
Paschen et al., 2003; Truettner et al., 2009; Urban et al., 2009), and
this effect was correlated with a small upregulation of GRP78 and
GRP94 protein levels in the hippocampus of rats subjected to the
two-vessel occlusion brain ischemia model (Truettner et al., 2009).
A significant upregulation of GRP78 protein levels was also
observed in the ischemic territory after transient MCAO in mice
(Shibata et al., 2003).
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induction of ER stress indicators in brain ischemia. However,
additional studies are required to determine their relative role in
neuronal death.
1.4. Autophagy in brain ischemia
Macroautophagy (autophagy from hereafter) represents the
degradation of any kind of intracellular components in the
lysosomes, and starts with the formation of a double membrane
vesicle (autophagosome) that sequester portions of the cytoplasm
that, when fused with the lysosome (autolysosome), allows the
degradation of cargo content by lysosomal proteases (Yang and
Klionsky, 2009). This quality control mechanism is highly active
under physiological conditions being responsible for the regulation
of mitochondrial turnover and clearance of protein aggregates
(Choi et al., 2013). Mice lacking the essential autophagic genes
Atg5 and Atg7 in the central nervous system showed reduced
lifespan, massive neuronal death, formation of inclusion bodies
and accumulation of ubiquitinated proteins (Hara et al., 2006;
Komatsu et al., 2006). However, little is known about how this
pathway is altered after brain ischemia.
An increase in autophagosomes, autolysosomes and LC3-II
protein levels was observed in CA1 neurons after 20 min of 2-
vessel occlusion in rats followed by 4–24 h of reperfusion,
suggesting activation of autophagy (Liu et al., 2010). However,
when lysosome inhibitors were applied, LC3-II protein levels failed
to elevate indicating an autophagic-flux impairment in the
hippocampus (Liu et al., 2010). An upregulation in LC3-II protein
levels was also observed during reperfusion after 1 h of transient
MCAO, but in this case no changes in the autophagic-flux were
observed in the penumbra region (Zhang et al., 2013a). This
discrepancy may be due to the differences in the methodology
used to induce brain ischemia (global vs focal ischemia) and or to
intrinsic properties of the brain region analysed, which was
different in the two sets of experiments. The class III phosphoi-
nositide 3-kinase (PI3K) inhibitor 3-methyladenine (3-MA), a well-
known inhibitor of autophagosome expansion thus inhibiting
autophagy, further increased the infarct volume after transient
MCAO and reinforced apoptotic cell death 24 h after OGD in
cultured cerebrocortical neurons (Zhang et al., 2013a). This
increase in vulnerability to OGD in the presence of 3-MA was
due to the defective mitochondrial clearance by the autophagic
pathway thus failing in aborting apoptosis (Adhami et al., 2007;
Zhang et al., 2013a). At this point it is still not understood how
lysosomes are involved in inducing apoptosis under ischemic
conditions. One possible mechanism is through a Bax-dependent
lysosomal-membrane permeabilization with the consequent
cathepsin B and D translocation to the cytosol, thereby triggering
apoptosis (Erdal et al., 2005).
Autophagy was also shown to play a role in ischemic tolerance.
Pheochromocytoma PC12 cells subjected to 6 h of ischemic pre-
conditioning showed a decreased survival when further exposed to
lethal-OGD for 15 h in the presence of 3-MA (Park et al., 2009).
Ischemic preconditioning (30 min), 24 h prior to a lethal exposure
to OGD in the presence of 3-MA abolished the upregulation of
HSP70, HSP60 and GRP78 (protective markers), and upregulated
CHOP, cleaved caspase-12 and caspase-3 (Sheng et al., 2012). These
alterations suggest that autophagic induction during ischemic
preconditioning reduces the excessive ER stress caused by harmful
ischemia (Sheng et al., 2012).
2. UPS
The ubiquitin–proteasome system (UPS) is the major intracel-
lular machinery for protein degradation (Ciechanover, 1994). UPSprotein targets are first polyubiquitinated before being degraded
by the proteasome. Under basal conditions, UPS components are
found in all subcellular components including the nucleus, plasma
membrane and mitochondria, and are responsible for maintaining
cellular homeostasis by regulating several important processes
such as cell division, cell death, signal transduction and
transmembrane transport (Wagner et al., 2011).
2.1. Ubiquitin
Ubiquitin is a small, heat-stable and highly conserved 76-amino
acid protein with 8.5 kDa, which can be covalently attached to
other proteins (Hershko and Ciechanover, 1998; Fang and Weiss-
man, 2004). Ubiquitin was first described as a thymic hormone and
to have lymphocyte-differentiation properties (Goldstein, 1974;
Goldstein et al., 1975; Schlesinger et al., 1975; Hershko and
Ciechanover, 1998), before its role in selective degradation of
proteins was uncovered. Additional studies were required to
identify a small protein, named APF-1 (ATP-dependent proteolysis
factor 1), which was shown to play an important role in the
selective degradation of APF-1 modified proteins (Ciechanover
et al., 1978, 1980). Later on, given the similarities on the amino acid
sequence and physical properties, it was found that APAF-1 was
indeed ubiquitin (Wilkinson et al., 1980).
Substrate proteins can be modified either by a monoubiquitin,
multiple monoubiquitin (multi-ubiquitination) or by a polyubi-
quitin chain (polyubiquitination). For the latter process, any of the
seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48,
Lys63) of ubiquitin can be linked to the previous one, resulting in a
sizeable increase of the chains with different configurations
(Grabbe et al., 2011). In an early attempt to quantify the relative
abundance of polyubiquitin chains, using an yeast model, it was
found that K48 polyubiquitin chains are the most abundant ones
(29%), followed by K11 (28%), K63 (16%), K6 (10.9%), K27 (9%), K33
(3.5%) and K29 (3.2%) (Xu et al., 2009b). However, the amount of
proteins that are single ubiquitinated was not assessed in this case.
A different study also performed in yeast showed that 56% of all
ubiquitin modified proteins are either monoubiquitinated or have
an end-cap ubiquitin, and the remaining bulk is given to
polyubiquitin modified proteins (Ziv et al., 2011). In this case
the relative abundance of different types of polyubiquitin chains
was quite different from the early observations in yeast: the K48
polyubiquitin chains were once again the most prevalent ones
(21%), followed by K63 (18%), K29 (5%), K11 (0.6%), K33 (0.1%)
and K27 (0.1%), while K6 was not detected (Ziv et al., 2011). These
differences may result from the different experimental approaches
used in both works.
The myriad of polyubiquitin modifying possibilities is respon-
sible for the high complexity of this system, thus regulating
different outcomes in the modified protein. While K48 poly-
ubiquitin chains target proteins for proteasomal degradation in a
process that requires at least four ubiquitin molecules (Fang and
Weissman, 2004; Ye and Rape, 2009; Lander et al., 2012), non-
canonical K63 polyubiquitin chains are associated with non-
proteolytic functions (Nathan et al., 2013) such as DNA repair,
kinase activity modulation (Pickart, 2004; Chernorudskiy and
Gainullin, 2013), regulation of plasma membrane protein inter-
nalization through the endocytic pathway, and delivery of
internalized proteins for lysosomal degradation (Grabbe et al.,
2011; Wagner et al., 2011). The ubiquitination process is also
important as a protein quality control mechanism. Initial studies
have shown that almost 30% of the newly synthesized proteins
arise as defective ribosomal products, being part of them
ubiquitinated (Schubert et al., 2000). However, the extent of
ubiquitination in the defective ribosomal products and whether
these proteins are ubiquitinated after or during the translation
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studies further addressed this issue using yeast as a model, but
although similar approaches were used, distinct results were
obtained. One report showed ubiquitination in 12–15% of newly
synthetized proteins while translation is occurring, being the effect
enhanced by misfolding agents and HSP70 inhibitors (Wang et al.,
2013). The same authors showed that protein ubiquitination
induced by misfolding agents is prevented by ubiquitin mutants
lacking lysine 48 (Wang et al., 2013). In contrast, the other study
reported that cotranslational ubiquitination occurs at a rate of 1–
5% under basal conditions by a mechanism dependent on the
activity of the Hul5, Hrd1 and Doa10 E3 ligases (Duttler et al.,
2013).
The importance of Lys11-linked polyubiquitin chains in
regulating cell cycle has been recently updated (Wickliffe et al.,
2011), and along with Lys6, Lys27 and Lys29, Lys33-linked
polyubiquitin chains can also direct proteins for proteasomal
degradation (Xu et al., 2009b; Kim et al., 2011; Kulathu and
Komander, 2012). In addition, several studies have shown the
crosstalk between ubiquitination and other post-translational
modifications, including phosphorylation and acetylation, thereby
increasing the complexity of this signaling network (Beltrao et al.,
2012). Surprisingly, in some cases, mono- and multi-monoubi-
quitination can also act as proteasomal degradative signals
(Guterman and Glickman, 2004; Boutet et al., 2007; Dimova
et al., 2012; Shabek et al., 2012).
2.2. Ubiquitination machinery
As a post-translational modification, the ubiquitination process,
i.e., the process of adding ubiquitin to a substrate protein, and the
removal of these ubiquitin molecules at a later point, is a finely
tuned process governed by a cascade of ubiquitination enzymes
and by deubiquitinating enzymes (DUBs), respectively. Almost 3%
of the human genome is devoted to the ubiquitination machinery
highlighting the importance of this process in cell survival and
homeostasis.
Protein ubiquitination occurs through a sequential action of
three or four different classes of enzymes, E1 or ubiquitin
activating enzyme, E2 or ubiquitin conjugating enzyme and E3
or ubiquitin ligase (Fig. 2). The human genome encodes for 2 E1s,Fig. 2. Main components of the ubiquitin–proteasome system. In order to be attached to
ATP-dependent manner, and further transferred to the E2-conjugating enzyme. The s
ubiquitination of a specific substrate. When a proper chain is assembled, with at least 
regulatory particle. This unfolding process allows the protein to enter the 20S catalytic pa
and b5 (chymotrypsin-like activity) subunits. At the end, small peptides are generated40 E2s and 650 E3s (Ye and Rape, 2009; de Bie and Ciechanover,
2011). E1 is the first enzyme involved in the ubiquitination
cascade. It binds to Mg2+-ATP and subsequently to ubiquitin in
order to activate its C-terminal Gly residue (Jin et al., 2007; Finley
et al., 2012). ATP hydrolysis generates an ubiquitin adenylate,
followed by ubiquitin transference to a Cys residue of E1 through a
thiol-ester linkage, with the release of adenosine monophosphate
(AMP) (Hershko et al., 1983; Jin et al., 2007). Since this activating
step is sequentially repeated, each fully loaded E1 carries two
molecules of ubiquitin, one as a thiol-ester and the other as an
adenylate (Fang and Weissman, 2004; Finley et al., 2012).
Activated ubiquitin is then transferred to a conserved core domain
of 150 residues (ubiquitin-conjugating (UBC) domain) of an E2
conjugating enzyme that includes an invariant cysteine residue
responsible for accepting ubiquitin from E1 (Fang and Weissman,
2004; Ye and Rape, 2009). In the third step, ubiquitin is transferred,
specifically, to a substrate protein by an E3 ligase. Two different
classes of E3 ligases are responsible for the interaction with the E2
conjugating enzymes and can serve either as catalytic intermedi-
ates, or mediate the direct transfer of ubiquitin to the substrate.
Homologous to E6-AP Carboxyl Terminus (HECT) E3 ligases serve
as intermediate ubiquitin acceptors through the formation of a
thiol-ester linkage between ubiquitin and the Cys residue in the
HECT domain before ubiquitin is attached to the substrate (Fang
and Weissman, 2004; de Bie and Ciechanover, 2011). On the other
hand, Really Interesting New Gene (RING) E3 ligases act only as
‘‘scaffold’’ proteins forming an E2-substrate protein complex that
allows the direct transfer of ubiquitin to the target protein (Fang
and Weissman, 2004; Deshaies and Joazeiro, 2009; de Bie and
Ciechanover, 2011). Despite the differences in the mechanisms of
ubiquitin transference to the substrate proteins, both types of E3
ligases lead to the formation of an isopeptide bond between the C-
terminal Gly of ubiquitin and a e-NH2 group of an internal Lys of
the substrate. However, ubiquitin can also be added to other
residues (recently reviewed in de Bie and Ciechanover, 2011).
While the interaction between the E2 and E3 determines the
type of polyubiquitin linkage, an additional subset of enzymes, E4,
or ubiquitin elongating enzymes, allows the elongation of
ubiquitin chains on those proteins that have been modified
by activated ubiquitin (Koegl et al., 1999; Hoppe, 2005; Finley
et al., 2012). the substrate protein, ubiquitin is first activated by the E1-activating enzyme in an
ubstrate-specificity of this pathway is given by the E3 ligase, which allows the
four ubiquitin moieties, it is recognized, unfolded and deubiquitinated by the 19S
rticle where it is degraded by the b1 (trypsin-like activity), b2 (caspase-like activity)
 and ubiquitin is regenerated.
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The ubiquitination process can be counteracted by deubiqui-
tinating enzymes (DUBs). Five major classes of DUBs have been
described: ubiquitin C-terminal hydrolases (UCHs), ubiquitin-
specific proteases (USPs), Machado–Joseph disease protein
domain proteases, ovarian tumor proteases and JAMM motif
proteases (Love et al., 2007). Almost all DUBs are cysteine
proteases, except the JAMM family which are metalloproteases
(Todi and Paulson, 2011). DUBs may be intrinsic to the 26S
proteasome (e.g. Rpn11), or may associate reversibly with the
proteasome (e.g. Uch37 and Usp14) (Koulich et al., 2008; Tai et al.,
2010; Liu and Jacobson, 2013), but most of them have a cytosolic
localization. The overall function of DUBs is to cleave ubiquitin-
linked molecules after the C-terminus of the last residue of
ubiquitin (Gly76), being essential to: (i) the maintenance of
monomeric ubiquitin pool, either by cleaving the ubiquitin
precursor or by trimming polyubiquitin chains; (ii) rescue
proteins targeted for degradation, allowing the cell to adapt
quickly to physiological changes, and (iii) prevent ubiquitin–
proteasome dependent protein degradation (Guterman and
Glickman, 2004; Komander et al., 2009). Activation of the DUBs
Usp14 and Uch37, either by polyubiquitin chains or their chemical
mimetics, stimulates the 19S associated ATPases thereby opening
the 20S closed gate, and thus promoting peptide hydrolysis (Peth
et al., 2009, 2013).
2.4. Proteasome
The 26S proteasome is a 2.5 MDa multisubunit complex
responsible for controlled ATP-dependent degradation of poly-
ubiquitinated proteins (Xie, 2010). It is composed of a catalytic 20S
core particle (CP or 20S proteasome) associated with one (RP1CP)
or two (RP2CP) 19S regulatory particles (RP or 19S proteasome),
that are responsible for detecting, deubiquitinating and unfolding
ubiquitinated proteins (da Fonseca et al., 2012; Djakovic et al.,
2012). Although RP1CP and RP2CP can be observed in several cell
types, including neuronal, kidney and liver cells, the proportion of
RP1CP and RP2CP to free 20S proteasome is often higher in neurons
(Tai et al., 2010). The highest amount of RP1CP is thought to be
better suited for performing a vectorial process which involves
substrate capture and release (Baumeister et al., 1998). The 26S
proteasome consists of at least 66 resident subunits and associated
proteins, e.g. E3 ligases and assembling factors, such as molecular
chaperones and others (Leggett et al., 2002; Tai et al., 2010; Xie,
2010).
Once a protein is committed for proteasomal degradation, by
linking at least four ubiquitin moieties and a proper polyubiquitin
chain (Glickman and Ciechanover, 2002; Lander et al., 2012), the
interaction with the 26S proteasome and subsequent deubiqui-
tination allows the translocation to the proteasome followed by
degradation (Fig. 2). At the end, small peptides ranging from 2 to 20
amino acids and free ubiquitin are regenerated (Glickman and
Ciechanover, 2002). The catalytic activity of the 26S proteasome is
significantly enhanced in the presence of ubiquitinated substrates
whereas the 20S activity remains unchanged (Peth et al., 2009).
This supports a role for the 26S proteasome in the selective
degradation of ubiquitinated substrates.
The 20S proteasome is a 670 kDa barrel-shaped structure
composed of 28 subunits arranged in a four stacked ring
structure: two a1–7 outer rings and two b1–7 inner rings (da
Fonseca and Morris, 2008). In the center of the ring, there is a
narrow pore where a protein targeted for degradation can enter
in an unfolded state. In the free CP this pore is closed by the N-
terminus of the a-subunits, namely a2, a3 and a4 (Xie, 2010).
However, the truncation of the a3 N-terminal is enough to keepthe pore open and increases the degradation of small peptides
(Peth et al., 2009). Besides closing the pore, a-subunits are also
responsible for compartmentalizing the catalytic b-subunits,
thereby preventing uncontrolled cleavage of cytosolic proteins.
Moreover, a proteomic approach revealed that the a7 subunit
interacts with proteins involved in the processing and splicing
of RNA (Fedorova et al., 2011). The b ring also forms a
central chamber where the peptidylglutamyl-like (cleaving
after acidic residues), trypsin-like (cleaving after basic residues)
and chymotrypsin-like (cleaving after hydrophobic residues)
activities of the 20S proteasome are mediated by the b1, b2
and b5 subunits, respectively (Fig. 2) (Groll et al., 1997; Beck
et al., 2012).
The other component of the 26S proteasome, the 19S regulatory
particle (RP), is a 700 kDa multisubunit complex composed of at
least 18 subunits. The 19S proteasome serves to recognize,
deubiquitinate and unfold the substrate proteins in order to make
them suitable to enter into the 20S catalytic pore. It is divided in
two biochemically distinct sub-complexes: the lid and the base
(Hershko and Ciechanover, 1998; Sakata et al., 2012; Tomko and
Hochstrasser, 2013). The lid consists of eight non-ATPase subunits,
Rpn3, Rpn5–9, Rpn12 and Rpn11 (a DUB enzyme). The base
contains six distinct AAA+ ATPases, Rpt1–6, and four non-ATPase
subunits, Rpn1, Rpn2, Rpn10 and Rpn13 (Lander et al., 2012;
Tomko and Hochstrasser, 2013). The interaction of polyubiquiti-
nated proteins with the RP base occurs on two intrinsic proteins,
Rpn10 and Rpn13, which are apically located in order to better
capture ubiquitinated substrates (Sakata et al., 2012). Rpn10 binds
ubiquitin conjugates through its C-terminus Ubiquitin-Interacting
Motif (UIM), and a similar function is mediated by the Rpn13
subunit through a conserved amino-terminal region named
pleckstrin-like receptor for ubiquitin (Pru) domain (Husnjak
et al., 2008; Schreiner et al., 2008; Sakata et al., 2012). The Pru
domain is also important to attach Rpn13 to the proteasome
(Schreiner et al., 2008).
Although recognition of ubiquitinated proteins is, to a certain
extent, considered to be a stochastic process, several proteins such
as Rad23 and Dsk2 have been shown to act as shuttling factors and
direct ubiquitinated proteins to the 26S proteasome (Guerrero
et al., 2006). These proteins interact with large scaffold proteins of
the base, namely Rpn1 and Rpn2 (Husnjak et al., 2008). Another
shuttling factor, the p62/sequestosome1, associates with the 26S
proteasome through the N-terminal domain (Seibenhener et al.,
2004; Myeku and Figueiredo-Pereira, 2011), and participate in the
selective recognition and degradation of ubiquitinated cargo by
selective autophagy (Lamark et al., 2009). While Rpn1 is
responsible for binding shuttling factors such as Rad23 and
Dsk2 (Elsasser et al., 2002, 2004; Rosenzweig et al., 2012), and the
non-obligatory deubiquitinating enzyme Ubp6/Usp14 (Leggett
et al., 2002; Elsasser et al., 2004; Rosenzweig et al., 2012), Rpn2
only binds the Rpn13 subunit (Schreiner et al., 2008; Rosenzweig
et al., 2012). This specific binding and the delivery of ubiquitinated
proteins to the proteasome by shuttling factors is driven by the N-
terminal ubiquitin-like domain (UBL), while the C-terminal
ubiquitin associated domain (UBA) is responsible for ubiquitin
binding (Rosenzweig et al., 2012).
The ATPase ring of the 19S proteasome is arranged in a spiral
case and constitutes the driving force to unfold and pull the target
proteins to be degraded inside the catalytic core (Lander et al.,
2012). The Rpt2 subunit appears to be the only one required for CP
opening and substrate entry (Kohler et al., 2001). Two independent
studies attributed another function to the base ATPases, in
preventing protein aggregation, by acting as chaperones, and in
mediating protein refolding and not unfolding (Braun et al., 1999),
and the Rpt5 subunit may also bind polyubiquitin chains as shown
by crosslinking studies (Lam et al., 2002).
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In response to viral, bacterial or other types of stress, the
constitutive catalytic subunits b1, b2, and b5 can be replaced by
three inducible subunits, low molecular weight protein 2 (LMP2 or
b1i), multicatalytic endopeptidase complex like 1 (MECL1 or b2i),
and b5i (LMP7), respectively (Loukissa et al., 2000). The protea-
somes containing these subunits are usually referred to as
immunoproteasome (i-proteasome). However, a mixture of the
standard and i-proteasome catalytic subunits may be found at the
20S catalytic core (Dahlmann et al., 2000), and was shown to
contribute to differences in catalytic core enzymatic characteristics
and cleavage of model substrates (Dahlmann et al., 2000). The i-
proteasomes play an important role in the immune system,
generating immunogenic peptides for antigen presentation on
MHC class I and recognition by cytotoxic T lymphocytes (Rock
et al., 1994; Goldberg et al., 2002). Although in young healthy
human brain i-proteasomes are almost absent, they have been
detected in brain areas from elderly subjects as well as from
patients affected by Alzheimer (Mishto et al., 2006) and
Huntington diseases (Diaz-Hernandez et al., 2003), and in Multiple
Sclerosis (Mishto et al., 2010). Transient focal cerebral ischemia
was also shown to upregulate the protein levels of i-proteasome
subunits LMP2 and LMP7 in the parietal cortex and hippocampus
(Lu and Wang, 2012). This upregulation of i-proteasomal subunits
may contribute to recover the proteasomal activity following a
transient cerebral ischemic stroke, leading to efficient clearance of
unwanted proteins and thus possibly providing neurons an
increased tolerance to transient ischemia.
3. Role of UPS in nervous system
In yeast cells, the majority of proteasomes have been detected
in the cell nucleus (Russell et al., 1999). However, in mammalian
cells, proteasomes are mainly located at the cytoplasm, with a very
high concentration close to centrosome (Wigley et al., 1999). By
contrast, i-proteasomes are specifically positioned at the endo-
plasmic reticulum (Brooks et al., 2000). A nuclear localization
signal may also direct proteasomes to the cell nucleus (Tanaka
et al., 1990; Reits et al., 1997), namely after induction of cell stress
(Ogiso et al., 2002), where they accumulate in focal subdomains
(von Mikecz, 2006). Human plasma also contains 20S proteasomes,
which were probably released from dying cells, and can potentially
be used as diagnostic markers (Wada et al., 1993; Lavabre-
Bertrand et al., 2001; Egerer et al., 2002).
Neurons are a very specialized post-mitotic cell type, and
several components of the UPS are present in both pre- and
postsynaptic compartments. In the nervous system, the UPS
regulates several aspects of synaptic function, such as spinogenesis
(Hamilton et al., 2012), presynaptic neurotransmission (Will-
eumier et al., 2006; Jiang et al., 2010), long-term potentiation
(Dong et al., 2008; Cajigas et al., 2010; Pavlopoulos et al., 2011),
synaptic scaling (Hou et al., 2011), apical dendrite outgrowth/
polarization (Hamilton and Zito, 2013; Miao et al., 2013; Vadhvani
et al., 2013), dendritic arborization (Puram et al., 2013), axon
growth (Yang et al., 2013), and synapse formation and elimination
(Yi and Ehlers, 2007).
Rat cerebrocortical cell extracts possess a higher proportion of
26S proteasomes (57%), when compared to HeLa cells (39%) and
to rat liver/kidney cell extracts (51%) (Tai et al., 2010). This
difference may suggest that selective protein degradation is a more
prominent and controlled process in the brain when compared to
other organs. In the rodent brain tissue, the mean levels of
unconjugated ubiquitin (122.6 pmol/mg) are comparable to the
conjugated form (111.6 pmol/mg), and the proportion of poly-
ubiquitin chains are to a certain extent similar to those observed inyeast cell extracts (K48 > K63 > K11 > K6 > K33 > K27 > K29)
(Na et al., 2012). This points towards the importance of the UPS
in the nervous system, and suggests that selective protein
degradation is a highly controlled process.
Synaptic activity can alter significantly the neuronal proteome
within minutes after postsynaptic receptor activation. In fact,
several components of the UPS can also be regulated upon NMDAR
activation (Colledge et al., 2003; Ehlers, 2003). Studies performed
in cultured hippocampal neurons showed that increasing synaptic
activity enhances proteasome activity and induces a redistribution
of the 26S proteasome from dendritic shafts to dendritic spines, as
shown using the degradation reporter UbG76V-GFP and the
proteasome reporter Rpt1-GFP, respectively (Dantuma et al.,
2000; Bingol and Schuman, 2006). These effects were promoted
by Rpt6 phosphorylation on the serine 120 residue by CaMKIIa
(Djakovic et al., 2009; Djakovic et al., 2012), and prevented by
CaMKII inhibition (Djakovic et al., 2009) or by knocking down
CaMKIIa with iRNA (Bingol et al., 2010). Similarly, activation of
NMDAR also stimulates the Ubiquitin C-terminal Hydrolase L1
(UCH-L1), thereby increasing free monomeric ubiquitin levels
(Cartier et al., 2009). This contrasts with the results obtained using
light-controlled excitation of individual presynaptic terminals of
hippocampal neurons, which increased polyubiquitin conjugation
but was without effect on the redistribution of free ubiquitin and
proteasomes (Hou et al., 2011). Furthermore, upregulation of
excitatory activity by incubation of hippocampal neurons with
bicuculline for 48 h was shown to increase ubiquitin conjugation in
postsynaptic density fractions (Ehlers, 2003).
Postsynaptically, the UPS is responsible for regulating the levels
and/or localization of several proteins. For example, the NMDAR
subunits, GluN1 and GluN2B, are regulated in an activity-
dependent manner by the Fbx2 and Mind Bomb-2 (Mib2) E3
ligases, respectively (Kato et al., 2005; Jurd et al., 2008) (Fig. 3). The
postsynaptic scaffold proteins PSD-95, Shank and GKAP undergo
selective activity-dependent ubiquitination (Ehlers, 2003), and
while the Murine-double minute 2 (Mdm2) is the putative E3
ligase for PSD-95 (Ehlers, 2003; Tsai et al., 2012), knockdown of
endogenous TRIM3 E3 ligase increases the protein levels of
guanylate kinase-associated protein (GKAP) and Shank (Hung
et al., 2010), suggesting that these two proteins may share a
common E3 ligase (Fig. 3). GKAP phosphorylation by CaMKIIa on
Ser54 promotes its removal from synaptic sites, polyubiquitination
and subsequent degradation by the proteasome (Shin et al., 2012).
All these synaptic proteins and others (e.g. bassoon, vesicular
glutamate transporter 1 and 2, vesicle-associated membrane
protein, synapsin) were shown recently to be modified by
ubiquitin, in a proteomic study using an antibody that recognizes
a specific signature (K-GG peptides) generated after trypsinization
of ubiquitin-modified proteins (Na et al., 2012).
The UPS also mediates the internalization of several membrane-
associated synaptic proteins. The initial studies showed that
AMPA-induced internalization of AMPAR was abolished by the
proteasome inhibitor MG132, but no ubiquitination of AMPAR
subunits was observed at that time (Patrick et al., 2003). Additional
studies suggested that this internalization is due to a reduced
stabilization of AMPA receptors into synaptic sites as a result of
PSD-95 degradation (Colledge et al., 2003). More recently, Nedd4
(neuronal-precursor cell-expressed developmentally downregu-
lated gene 4) was identified as the putative E3 ligase for GluA1
(Schwarz et al., 2010), and knockdown of Nedd4 prevented GluA1
C-terminal K868 residue ubiquitination, abolishing AMPAR inter-
nalization (Lin et al., 2011) (Fig. 3). The AMPAR GluA2 subunit is
also ubiquitinated in response to bicuculline treatment (Lussier
et al., 2011). Yet, the E3 ligase responsible to ubiquitinate GluA2
subunit differs from the one responsible for GluA1 ubiquitination.
The available evidences suggest that the RNF167 E3 ligase is
Fig. 3. Regulation of synaptic proteins through the ubiquitin–proteasome system. The post-synaptic region is enriched in several proteins of the UPS (e.g. ubiquitin, E3 ligases,
DUBs). (A) Synaptic activity induces the trafficking of the 26S proteasome from the dendritic shafts to dendritic spines through association with the actin cytoskeleton. This is
promoted by phosphorylation of the 26S proteasome-associated protein Rpt6 on Ser120 by CaMKIIa. In addition, the post-synaptic proteins PSD-95 and GKAP are
ubiquitinated by the Murine-Double Minute 2 (Mdm2) and Trim3 E3 ligases, respectively. The removal of GKAP from the synaptic sites and consequent ubiquitination is
mediated by CaMKIIa-dependent phosphorylation on Ser54. Shank is also ubiquitinated but the putative E3 ligase involved remains to be identified. (B) The endocytosis of
AMPAR is also ubiquitin-dependent. Neuronal activity induces the ubiquitination of GluA2 and GluA1 subunits by the RN167 and Nedd4 E3 ligases, respectively.
Ubiquitination of the GluA1 subunit occurs at the C-terminal Lys868. The internalization of AMPAR can also be modulated by regulating Arc protein levels, a protein involved
in the endolysosomal transport of AMPAR, by the E3 ligase Ube3A. Additional functions have been attributed to Ube3A such as in regulating Golgi acidification. (C) Different
E3 ligases can also act on these receptors depending on their subunit composition. The GluN2B subunit is ubiquitinated by the Mib2 E3 ligase in response to neuronal activity,
whereas the obligatory GluN1 subunit is ubiquitinated by the Fbx2 E3 ligase. This occurs when the subunit is internalized and at the endoplasmic reticulum level.
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this ligase was shown to increase AMPAR mediated currents by
increasing the surface expression of GluA2 and to reduce GluA2
ubiquitination following bicuculline treatment (Lussier et al.,
2012) (Fig. 3). There is still some controversy regarding the
mechanism of AMPAR internalization promoted by synaptic
activity, and in particular the role of ubiquitin-mediated degrada-
tion. While some studies showed that internalization and
degradation is blocked by proteasome inhibitors (Hou et al.,
2011; Lin et al., 2011), others revealed a dendritic co-localization of
the internalized receptors with the lysosomal marker Lamp1A,
suggesting that internalized receptors are delivered to the
lysosomes (Schwarz et al., 2010). Since the internalization of
plasma membrane proteins through the endocytic pathway can be
mediated by non-canonical polyubiquitin chains (Groothuis et al.,
2006), the decreased degradation in the presence of proteasome
inhibitors can still be attributed to the lysosomes since under these
conditions there is a decrease in free ubiquitin levels thus
interfering with the ubiquitin-mediated internalization process
(Dantuma et al., 2006).
Dysfunction of the ubiquitination and deubiquitination ma-
chineries, mutations in ubiquitin, proteasomal impairment, and
mutations in proteasome substrates affecting their rate of
degradation underlie the pathogenesis of many neurodegenerative
diseases (Dennissen et al., 2012). For instance, the ataxic mouse(axJ), which results from a mutation in the ataxia gene encoding for
the DUB Usp14, shows deficits in presynaptic neurotransmitter
release and short-term plasticity (Wilson et al., 2002), in addition
to a 35% decrease in free ubiquitin levels when compared to wild-
type mice (Walters et al., 2008). Usp14 overexpression rescued the
levels of free ubiquitin in the brain, as well as the lifespan and
motor activity of axJ mice to values similar to the wildtype
(Crimmins et al., 2006). Notably, all the negative effects observed
in the axJ phenotype were attributed to the decreased free
ubiquitin levels, resulting ultimately in synaptic dysfunction.
Restoring free ubiquitin levels prevented the early death at 8
weeks of age, body weight loss and presynaptic dysfunction
observed in the ataxic mice (Chen et al., 2011). The deficit in
neurotransmitter release in the axJ mice is in accordance with the
results showing that inhibition of Uch-L1, another DUB abundantly
expressed in neurons, also decreases free ubiquitin levels, thus
increasing the number of synaptic vesicles (Cartier et al., 2009).
Mutations in the RING finger E3 ligase Listerin, observed in the
lister mouse model, also induce biochemical, cellular and
neurological alterations similar to those observed in many
neurodegenerative processes, including deficits in balance and
motor coordination, dystrophic neurites, swollen mitochondria,
reduced number and caliber of motor neurons and hyperpho-
sphorylated Tau (Chu et al., 2009). This phenotype suggests a broad
effect in the regulation of the proteome. Additional studies, using
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is involved in the mechanism of quality control of proteins,
through association with the ribosomes (Bengtson and Joazeiro,
2010).
The UPS is also responsible of regulating social behavior and
interaction. A role for the UPS in mouse models of Fragile X and
Angelman Syndromes, two well-known forms of autism, was also
unraveled recently. The defective degradation of PSD-95, a process
required for synapse elimination, by the Mdm2 E3 ligase, may
underlie the excessive dendritic spine number observed in Fragile
X syndrome (Tsai et al., 2012). Reduced levels of the Ube3A protein
levels, an E3 ligase, has also been associated with the Angelman
Syndrome (Williams et al., 2010; Ebert and Greenberg, 2013). This
protein is upregulated by synaptic activity thereby controlling the
degradation of Arc, a protein involved in AMPAR endocytosis
(Greer et al., 2010). Arc protein is also involved in the mGluR-
dependent long-term depression through AMPAR endocytosis
(Waung et al., 2008), and its nuclear localization regulates
homeostatic plasticity by decreasing GluA1 transcription (Korb
et al., 2013). Knockout mouse models for Ube3A have reduced
hippocampal synaptic GluA1 receptors with a concomitant
decrease in AMPAR mediated current, and reduced levels of
mESPC (Greer et al., 2010). More recently, conditional neuronal
loss of Uba6, an E1 ligase involved in the specific activation of
ubiquitin, was shown to induce hyperactivity, social interaction
deficits, decreased spine density both in the amygdala and in the
CA3 region, and impaired learning and memory in mice (Jin et al.,
2007; Lee et al., 2013). Moreover, a more detailed biochemical
analysis showed that the levels of Ube3A, Shank and Arc were
elevated and decreased, respectively, in this mouse model (Lee
et al., 2013). The reduced spine density is in accordance with other
works showing that knockdown of Ube3A in pyramidal neurons
reduces apical dendritic outgrowth (Miao et al., 2013). However,
electrophysiological analysis of the synapses in this mouse model
is still lacking.
4. UPS in ischemic conditions
Despite recent advances, there are still major gaps in the
understanding of pathogenesis of cerebral ischemic injury and
therapeutic options for stroke patients are limited (Moskowitz
et al., 2010). Transient cerebral ischemia is associated with an
inflammatory response and a rapid and excessive production of
various misfolded proteins due to oxidative stress and other
mechanisms (Ge et al., 2007, 2012). Overproduction of damaged
proteins following ischemia is reflected in a pronounced increase
of conjugation of targeted proteins with ubiquitin (Hayashi et al.,
1992). Therefore, the accumulation of ubiquitin-containing protein
aggregates following ischemia is a general feature. However, the
factors leading to deposition of these aggregates and their
consequences for stroke outcome remain poorly understood.
4.1. UPS and in vivo ischemia models
Transient cerebral ischemia induces irreversible misfolded
protein aggregate formation. The first reports showed that brief rat
forebrain ischemia, induced by bilateral common carotid occlusion
combined with a reduction of the mean arterial blood pressure to
50 mmHg, evoked a selective and sustained loss of ubiquitin
immunoreactivity in rat hippocampal CA1 neurons (Magnusson
and Wieloch, 1989). However, a few years later, it was shown that
the loss of ubiquitin immunoreactivity in gerbil hippocampal CA1
neurons after ischemia induced by bilateral carotid occlusion
(BCO) was a result of free ubiquitin depletion and did not arise
from ubiquitin conjugation (Morimoto et al., 1996). It was also
shown that BCO-induced transient ischemia in gerbils promotes atransient consumption of free ubiquitin associated with an
increase of conjugated multiubiquitin chains in hippocampal
CA3 and dentate gyrus regions, where neurons survive, but these
changes are persistent in the CA1 region, where neurons are more
vulnerable and destined to die after 5 min of ischemia (Ide et al.,
1999). Under the same experimental conditions, a transient
upregulation of the ubiquitin mRNA was observed in all
hippocampal neurons and in the cerebral cortex, with maximal
effects observed after 6 h of reperfusion, which then decreased to
control levels at 48 h (Ide et al., 1999). In a two-vessel transient
occlusion model of global ischemia in rats, dying neurons in the
hippocampal CA1 region also exhibited an accumulation of high-
molecular weight ubiquitin-conjugated proteins, which were
found in clusters around nuclei and close to the dendritic
membrane during 4–24 h reperfusion after 15 min ischemia; this
was not observed in CA1 neurons destined to survive or in the
dentate gyrus (Hu et al., 2000). Similar results were obtained at 1,
4, and 24 h of reperfusion after 2 h MCAO in rats, a model of focal
ischemia (Hu et al., 2001). The ubiquitin-positive immunoclusters
of misfolded/damaged protein aggregates were also found in
postsynaptic densities from hippocampal neurons of rats subjected
to 15 min of two-vessel occlusion model followed by 4 and 24 h of
reperfusion (Liu et al., 2004). Moreover, selective accumulation of
UBB+1, a mutant ubiquitin that is formed by dinucleotide deletion
in mRNA, causing misreading and production of an aberrant C-
terminus ubiquitin (van Den Hurk et al., 2001), which cannot
ubiquitinate target proteins, was also found in the cytoplasm of
CA1 neurons of gerbils submitted to 5 min of bilateral common
carotid arteries occlusion and reperfusion (Yamashiro et al., 2007).
This accumulation appeared at 30 min after ischemia in CA1 region
and increased up to day 4 after ischemia. The number of neurons
displaying UBB+1 accumulation was also increased from 30 min to
6 h after ischemia (Yamashiro et al., 2007). These changes were
found to precede neuronal death in the hippocampal CA1 region.
UBB+1 protein was also transiently expressed but did not
accumulate in the surviving neurons of the CA3 region, dentate
gyrus, and frontal cortex, suggesting that accumulation of UBB+1 is
specifically related to delayed neuronal death of CA1 neurons
(Yamashiro et al., 2007). Since UBB+1 can act as an endogenous
proteasome inhibitor (Lindsten et al., 2002), these observations
further point to a proteasomal dysfunction in the hippocampal CA1
region after ischemia and reperfusion. In summary, these results
suggest that ubiquitin-containing clusters of misfolded or dam-
aged proteins are formed in all post-ischemic neurons, primarily
during reperfusion. A recent study suggested that the 15-deoxy-
D12,14-prostaglandin J2 (15d-PHJ2) produced by a cyclooxygenase-
dependent mechanism after rat transient focal brain ischemia may
contribute to the aggregation of ubiquitinated proteins (Liu et al.,
2013). Accordingly, addition of 15d-PHJ2 to cultures cerebrocor-
tical neurons induced the accumulation and aggregation of
ubiquitinated proteins and downregulated the activity of the
proteasome (Liu et al., 2013).
The clusters of ubiquitinated proteins formed after brain
ischemia may give rise to protein aggregates by an unknown
process, possibly through translation arrest, but the aggregates are
maintained exclusively in CA1 neurons until their death (Hu et al.,
2000, 2001; Liu et al., 2004, 2005). In fact, translational complex
components are irreversibly clumped into large abnormal protein
aggregates after transient brain ischemia (Liu et al., 2005) or focal
brain ischemia (Zhang et al., 2006a), suggesting that the
irreversible inhibition of translation in neurons destined to die
after ischemia is caused by irreversible aggregation of translational
complex components, chaperones and protein folding enzymes.
Moreover, proteasomes, particularly the 19S RP, are also seques-
tered into these protein aggregates in post-ischemic brains (Ge
et al., 2007). Furthermore, cytoplasmic ubiquitin-containing
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neurons at day 2–3 of reperfusion following global forebrain
ischemia and may contribute to sustained translation arrest and
CA1 pyramidal neuron vulnerability (DeGracia et al., 2007).
Recent work also demonstrates that reperfusion rather than
ischemia leads to the accumulation of ubiquitin aggregates in the
neocortex, an area of more intense reperfusion, as well as in the
striatum after transient focal ischemia (MCAO) (Hochrainer et al.,
2012). However, no ubiquitin aggregates were found in permanent
ischemia and surprisingly proteasome impairment was greatest
under these conditions (Hochrainer et al., 2012), suggesting that
the two events are independent. Alternatively, the absence of
ubiquitin aggregates under the latter conditions may be attributed
to ATP depletion, which should prevent the activation of ubiquitin
by the ATP-dependent E1 ligase, thereby reducing protein
ubiquitination (Huang et al., 2013). Taken together, the available
evidence suggests that the formation of ubiquitin–protein
aggregates may reflect a greater potential for tissue survival in
the immediate postischemic period (Fig. 4). The cause and effect
relationship between protein aggregation and subsequent neuro-
nal death still remains to be determined and further studies are
needed to uncover the roles of ubiquitinated protein aggregation
after brain ischemia.
Accumulation of ubiquitin conjugated proteins and depletion of
free ubiquitin following an ischemic injury suggest impairment of
proteasome function. In fact, transient global brain ischemiaFig. 4. Overview of the consequences of brain ischemia on the UPS. Transient ischemia de
disassembly, leading to accumulation of ubiquitinated proteins and/or failure of the u
degradation by the UPS. After reperfusion of the injured area, 26S proteasomes are reques
there is a large amount of 26S targeted proteins, proteasome also become blocked. The ac
decrease after ischemic injury may also contribute to the failure of quality-control me
protective response of the cell against abnormal proteins.impairs 26S proteasome function by promoting proteasome
disassembly, both in rats (Ge et al., 2007) and gerbils (Kamikubo
and Hayashi, 1996; Asai et al., 2002). However, while the 26S
proteasome activity recovers in many regions after reperfusion
(e.g. CA3, dentate gyrus, and frontal cortex), in more vulnerable
areas, such as CA1 region of the hippocampus, the 19S and 20S
proteasomes do not fully reassociate, and the proteasome is
irreversibly inhibited (Asai et al., 2002). A time-dependent
decrease in proteasome activity has also been detected in
ipsilateral cortex and hippocampus during 1–24 h reperfusion
after transient focal ischemia (Keller et al., 2000), and this
downregulation of proteasome activity was partly attributed to
oxidative stress (Keller et al., 2000). Furthermore, it was shown
that proteasomes are disassembled after an episode of global brain
ischemia, partially because of ATP depletion (Fig. 4) (Asai et al.,
2002). It remains to be determined why the ATP-dependent
reassembly of 26S proteasome is selectively impaired in the
hippocampal CA1 region.
Transient forebrain ischemia induced by bilateral common
artery occlusion in Mongolian gerbils and transient focal brain
ischemia induced by MCAO in mice were without effect on the
expression of proteasome subunits, although a downregulation of
the proteasome activity was found in both cases (Kamikubo and
Hayashi, 1996; Keller et al., 2000). These evidences suggest that
posttranslational mechanisms are involved in the downregulation
of the proteasome in the ischemic brain. Transient focal cerebralcreases the ATP content of the affected areas, which contributes to 26S proteasome
biquitin activating enzyme (E1), thus decreasing the overall efficiency of protein
ted to degrade the accumulated ubiquitin conjugates and become sequestered. Since
cumulation of new misfolded proteins will lead to the formation of aggregates. ATP
chanisms, which also contribute to aggregate formation. Aggregate formation is a
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immunoproteasomal subunits (LMP2 and LMP7), both in the
nuclear and cytosolic compartments. These alterations were
mainly observed in neurons and considering that the i-proteasome
displays an increased proteolytic activity (van Deventer and
Neefjes, 2010) it may contribute to the recovery of the proteasome
activity following the ischemic insult. This delayed response may
increase tolerance to transient ischemia by allowing the clearance
of unwanted proteins.
In summary, brain ischemia induces an excessive accumulation
of ubiquitinated proteins, which are in excess to be degraded by
the proteasome (Fig. 4). The accumulation of ubiquitinated
proteins is further increased due to the impairment of the
proteasome activity, giving rise to aggregates that also contain
other unfolded/damaged proteins or organelles, as observed in
delayed neuronal death after brain ischemia.
4.2. Changes in the UPS in in vitro models of global ischemia
OGD, an in vitro model for transient global ischemia, was shown
to induce hippocampal neuronal death, through activation of
NMDA receptors, and to downregulate proteasome activity in a
NMDA receptor activation-dependent manner (Caldeira et al.,
2013). This OGD-induced decline on proteasome activity may be
due to a rapid ATP depletion. A decrease in ATP content was in fact
observed in cultured cortical neurons subjected to OGD followed
by reoxygenation (Chen et al., 2010) and in cultured hippocampal
neurons subjected to excitotoxic stimulation (see Section 4.3)
(Caldeira et al., 2013). However, irreversible ATP-independent
inhibition of proteasome activity was detected in hippocampal
CA1 neurons after transient forebrain ischemia (Asai et al., 2002),
suggesting that two different mechanisms may be involved in the
regulation of proteasome activity after OGD.
OGD followed by incubation in culture conditioned medium (to
mimic reperfusion) induces protein oxidative damage in cultured
cortical neurons. The upregulation in oxidized proteins is coupled
to an increase in protein degradation, both during and after OGD
(Weih et al., 2001). Inhibition of the proteasome was shown to
prevent proteolysis of oxidized proteins after OGD, suggesting a
role for the UPS in the clearance of oxidized proteins in neuronal
cells. Moreover, proteasomal activity was found to be similar
immediately after OGD and in sham-washed cultured cortical
neurons (Weih et al., 2001), in agreement with the relative
resistance of the proteasome against oxidative stress (Reinheckel
et al., 1998). However, these results contrast with the protein
aggregation and reduced cytosolic and nuclear free ubiquitin
distribution reported in the organotypic hippocampal slice culture
model of OGD (Ouyang et al., 2005). OGD followed by reoxygena-
tion induced a time-dependent ubiquitination of misfolded
proteins and aggregate formation, specially clustered near nuclei
of cultured cortical neurons (Chen et al., 2010). These effects seem
to be mediated by a dysregulation of endoplasmic reticulum Ca2+
concentration, which affects protein folding. Interestingly, endo-
plasmic reticulum Ca2+ dysregulation also partially affects
proteasome activity after OGD (Chen et al., 2010). These findings
point to the UPS as an active component of the cellular defense
system against oxidative stress after cerebral ischemia.
4.3. UPS in glutamate-induced excitotoxicity
Activation of NMDA receptors plays a role in neuronal death
induced by transient OGD in different neuronal culture systems
(Martinez-Sanchez et al., 2004; Bonde et al., 2005; Ahlgren et al.,
2011; Caldeira et al., 2013), similarly to the role of glutamate
receptors in neuronal damage in the ischemic brain [for review
(Kostandy, 2012)]. The activation of NMDA-type glutamatereceptors is likely to be a mediator in OGD and ischemia-induced
downregulation of the proteasome activity, as shown in experi-
ments where cultured hippocampal neurons were subjected to
excitotoxic stimulation with glutamate or with NMDA (Caldeira
et al., 2013). The downregulation of the proteasome activity after
excitotoxic stimulation with glutamate is specifically mediated by
activation of extrasynaptic NMDA receptors (Caldeira et al., 2013),
in agreement with their role in excitotoxic neuronal death
(Bengtson et al., 2008). In particular, the entry of calcium through
NMDAR channels is actively involved in the downregulation of the
proteasome activity, possibly due to activation of downstream
signaling pathways that target proteasome proteolytic activity.
The effects of excitotoxic stimulation with glutamate on the
activity of the proteasome, as measured with fluorogenic
substrates after native gel electrophoresis, correlate with a
disassembly of the 26S proteasome, by a mechanism that may
be related with the decrease in the ATP content (Caldeira et al.,
2013). These structural changes in the proteasome resemble the
alterations in the proteasome structure observed in brain ischemia
(Kamikubo and Hayashi, 1996; Asai et al., 2002; Ge et al., 2007),
further suggesting that overactivation of glutamate receptors plays
a key role in the downregulation of the proteasome in the ischemic
brain.
Although it is still unknown which are the signaling cascades
that mediate the downregulation of the proteasome activity in
brain ischemia, the activation of calpains and lysosomal cathepsins
are good candidates, given the fact that the toxic effects of
glutamate are partially mediated by the Ca2+-dependent activation
of calpains (Takano et al., 2005) and both proteases were shown to
be activated before downregulation of the proteasome in
hippocampal neurons subjected to excitotoxic stimulation (Melo
et al., 2013). Accordingly, a recent study showed a calpain-
mediated cleavage of the Rpn10 protein in cultured cortical
neurons with compromised ATP production, and the cleavage of
this subunit may affect the assembly of the 26S proteasome
(Huang et al., 2013). The lysosomal cysteine proteases, cathepsin-B
and cathepsin-L are also involved in ischemic cerebral damage
(Seyfried et al., 2001) and in proteasomal subunit degradation
(Cuervo et al., 1995). This is in agreement with the results showing
that the excitotoxicity-induced proteasome inhibition is partially
prevented by inhibition of cathepsin-L (Caldeira et al., 2013). Taken
together, these results suggest a cross-talk between different
families of proteases and the proteasome which is likely to regulate
the cell fate (Sun et al., 2004; Stoehr et al., 2013).
The studies on the effect of excitotoxic stimulation on the
activity of the proteasome showed a preferential targeting of
nuclear proteasomes in cultured hippocampal neurons (Caldeira
et al., 2013), but the differential effects when compared with the
cytoplasmic population of proteasomes are still not understood. In
addition to the changes in the activity of the proteasome, excessive
NMDAR stimulation in cultured cortical neurons was also shown to
induce hyperphosphorylation of the Anaphase-Promoting com-
plex/cyclosome (APC/C) Cdh1 activator protein, which leads to a
cytosolic accumulation of this E3 ligase responsible for the control
of cell cycle progression (Peters, 2002; Maestre et al., 2008). The
effect of excitotoxic stimulation is mediated by calpain cleavage of
cyclin-dependent kinase-5 (Cdk5), with formation of a p25 product
that induces the hyperphosphorylation of Cdh1 (Maestre et al.,
2008). In this case, the downregulation of the E3 ligase in the
nucleus allows the accumulation of cyclin B1 in this compartment,
thus inducing apoptotic cell death by abnormal entry in S-phase
(Almeida et al., 2005; Maestre et al., 2008). Excitotoxic stimulation
with glutamate also downregulated total DUB activity in cultured
hippocampal neurons although no effect was observed on the
activity of Uch-L1, showing that not all deubiquitinating enzymes
are affected (Caldeira et al., 2013). Together, these results suggest
M.V. Caldeira et al. / Progress in Neurobiology 112 (2014) 50–6962that the UPS is subjected to regulation at different levels in brain
ischemia, and differential effects may be expected in distinct
subcellular compartments.
Given the evidences pointing to a role of the UPS in the
regulation of glutamatergic synapses (see Section 3.2), the
downregulation of the proteasome observed in brain ischemia
may have important implications at this level. A neurotoxic insult
with glutamate (100 mM during 4 h) was shown to decrease the
number of PDS-95 puncta and to cause PSD loss, which was
accompanied by spine loss in cultured hippocampal neurons
(Waataja et al., 2008). These effects were attenuated by NMDA
receptor antagonists, but protective effects were also observed in
the presence of a proteasome inhibitor and by a genetic approach
expressing p14ARF (which binds and inhibits mdm2, an E3 ligase
known to ubiquitinate PSD-95, targeting the protein for protea-
somal degradation). This study suggests that glutamate activates
NMDA receptors to stimulate a Ca2+-dependent E3 ligase leading to
PSD-95 ubiquitination and degradation by the proteasome, with
consequent loss of PSD-95 clustering (Waataja et al., 2008). Taken
together, these evidences suggest that some of the alterations
resulting from proteasome inhibition in brain ischemia may
actually be protective. Accordingly, proteasome and calpain
inhibition did protect the neuronal markers for dendrites (MAP-
2), axons (Neurofilament-H) and the vesicular glutamate trans-
porters (VGLUT1-2) in cultured hippocampal neurons subjected to
excitotoxic stimulation (Melo et al., 2013).
Brain ischemia also has a strong impact in GABAergic
neurotransmission, and in particular the downregulation in the
postsynaptic expression of GABAA receptors largely contributes to
a decrease in inhibitory activity. Excitotoxic stimulation with
glutamate was shown to induce UPS-dependent cleavage of
glutamic acid decarboxylase (GAD; GAD65/67), the enzyme
involved in the synthesis of GABA, in cultured hippocampal
neurons (Baptista et al., 2010). GAD cleavage decreased enzyme
activity and changed the subcellular distribution of GAD65
(Baptista et al., 2010). These alterations are expected to decrease
GABA production and to downregulate GABAergic synaptic
transmission, thereby contributing to neuronal death.
Taken together, the available evidences show that excitotoxic
stimulation with glutamate has multiple effects on the ubiquitin–
proteasome system which may contribute to the demise process in
brain ischemia and in other neurological disorders.
4.4. UPS in ischemic tolerance
Ischemic tolerance is a neuroprotective mechanism in brain,
whereby prior exposure to a brief non-toxic ischemic event
induces protection to subsequent normal harmful ischemic insult
(for review see Meller, 2009). Two mechanisms of ischemic
tolerance have been described: (i) classical or delayed ischemic
tolerance, which requires protein synthesis and changes in the
genomic response, resulting in protection after 24–72 h after the
preconditioning stimulus (Barone et al., 1998), and (ii) rapid
ischemic tolerance, independent of new protein synthesis and
producing neuroprotection within 30 min to 1 h following the
preconditioning event (Meller et al., 2006), suggesting a role for
posttranslational mechanisms (for review Meller, 2009).
UPS has been shown to play an important role in both types of
ischemic tolerance. In fact, after delayed ischemic tolerance (5 min
of bilateral common carotid artery occlusion at 48 h of reperfusion
after a preconditioning stimulus of 2 min) the abundance of free
ubiquitin was found to be restored above the normal values, in
contrast with the ischemia-induced moderate and transient
reduction of free ubiquitin. Although the results suggest de novo
ubiquitin synthesis, no changes were observed in the ubiquitin
mRNA (Ide et al., 1999). A role of UPS on rapid tolerance to ischemiawas also described. A proteomic analysis (using ubiquitin pull-
down assay and mass spectrometry) of ubiquitinated proteins
showed an upregulation of 17 proteins in cultured cerebrocortical
neurons after a preconditioning ischemic event in vitro (OGD-pre-
treated cells) and 7 proteins were exclusive of control samples.
Moreover, it was shown that a cell death-associated protein, Bcl-2-
interacting mediator of cell death (Bim), is selectively ubiquiti-
nated and degraded by the proteasome in cultured cortical neurons
preconditioned with 30 min of OGD and 1 h of recovery followed
by 120 min of OGD and 24 h of post-incubation in culture
conditioned medium (Meller et al., 2006). These results suggest
a rapid degradation of cell death promoting proteins and rapid
neuroprotection by the UPS. Moreover, the UPS was found to
increase neuronal resistance to excitotoxicity through rapid
modulation of postsynaptic densities after preconditioning ische-
mia (Meller et al., 2008). Ubiquitination and degradation of
proteins involved in the structure and function of PSD, namely
MARCKS (myristoylated, alanine-rich C-kinase substrate) and
fascin (actin binding proteins), result in the reorganization of
actin cytoskeleton after preconditioning ischemia. These altera-
tions result in the loss of NMDAR from the PSD and a concomitant
selective attenuation of toxic NMDAR-mediated signaling at the
time when tolerance to ischemia is acquired (Meller et al., 2008).
Accordingly, inhibition of proteasome activity was found to block
the rapid ischemic tolerance-induced neuroprotection (Meller
et al., 2008). Accordingly, activation of NMDA receptors was shown
to induce PSD-95 degradation by the UPS, together with a loss of
dendritic spines, in cultured cerebrocortical neurons (Waataja
et al., 2008). The neuroprotective effects (cerebral infarct size,
memory and motor performance) induced by both acute and
delayed ischemia preconditioning are also attenuated when the
proteasome is inhibited with Z-Leu-Leu-Phe-CHO (Rehni et al.,
2010), further suggesting that immediate as well as prolonged
beneficial effects of ischemic preconditioning in global cerebral
ischemia and reperfusion (17 min BCAO followed by 24 h
reperfusion) may be attributed to UPS activity.
A recent report showed that ischemic postconditioning (three
cycles of 30 s reperfusion and 30 s reocclusion after 2 h of MCAO in
rat) can be neuroprotective, since it decreases the size of cerebral
infarction and increases the activities of superoxide dismutase,
catalase and proteasome, thereby decreasing the levels of oxidized
proteins and downregulating the formation of cytotoxic protein
aggregates (Li et al., 2012). Moreover, ischemic postconditioning
was also found to have a protective effect on hippocampal CA1
neurons (Liang et al., 2012). In this study, ischemic postcondition-
ing (15 min of two vessel occlusion transient global ischemia
followed by three cycles of 30 s reperfusion and 30 s clamping in
rat) prevented neuronal death in the hippocampal CA1 region
caused by transient ischemia and reperfusion (Liang et al., 2012).
This effect was accompanied by a decrease in ubiquitin containing
aggregates and partial inhibition of the effects of ischemia/
reperfusion on the proteasome activity and abundance (Liang
et al., 2012), suggesting that ischemic postconditioning rescued
neuronal death in the hippocampal CA1 region by suppressing the
formation of protein aggregates.
4.5. Protective effects of proteasome modulators in brain ischemia
The experimental evidence described in Sections 4.1 and 4.2
point to a downregulation of the UPS in brain ischemia, as observed
for example by an increase in the accumulation of ubiquitinated
proteins, which correlates with neuronal death. Furthermore,
injection of a proteasome inhibitor into the lateral ventricle of rats
significantly decreased NF-kB activity and resulted in apoptotic
neuronal death in various CNS areas, suggesting that proteasome
inhibition induces apoptotic neuronal death (Taglialatela et al.,
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proteasome inhibitors was shown to induce cell death (Keller
and Markesbery, 2000; Qiu et al., 2000; Bobba et al., 2002; Ding
et al., 2006). These results would further suggest that proteasome
inhibition contributes to neuronal death in brain ischemia.
However, in contrast with the evidence described above, protea-
some inhibitors were shown to provide neuroprotection in various
models of stroke.
CVT-634, the first proteasome inhibitor to be tested in a rat
model of focal brain ischemia, reduced infarction without affecting
regional cerebral blood flow (Buchan et al., 2000). A more detailed
characterization of the neuroprotective properties of proteasome
inhibitors in brain ischemia was provided with studies using
MLN519 (previously named PS519), a compound structurally
similar to lactacystin (Williams et al., 2003). The effect of MLN519
was tested using transient MCAO (Phillips et al., 2000; Williams
et al., 2003, 2004, 2005) and the cardioembolic stroke model
(Zhang et al., 2001), and a therapeutic window of 6–10 h after
ischemia/reperfusion brain injury was observed using the former
model. The neuroprotective effects of MLN519 were attributed to a
decrease in inflammation after the ischemic injury, through
downregulation of NF-kB and downstream inflammatory genes,
as well as inhibition of the infiltration of inflammatory cells into
the brain. The effects of the proteasome inhibitor were observed on
the ‘early’ and ‘delayed’ inflammatory responses after the ischemic
injury, characterized by neutrophil infiltration and macrophage
invasion, respectively, even with delayed treatments (Phillips
et al., 2000; Zhang et al., 2001; Berti et al., 2003; Williams et al.,
2003, 2004). A detailed immunohistochemical analysis of the cells
showing an increase in NF-kB immunoreactivity after transient
MCAO, showed the highest levels in leukocytes and endothelial
cells, but this effect was significantly reduced upon administration
of MLN519 (Williams et al., 2003). Furthermore, intravenous
administration of MLN519 significantly downregulated cell adhe-
sion molecules, particularly in endothelial cells (Berti et al., 2003).
Considering the cell specific effects of MLN519 and its relatively
poor penetration across the blood–brain barrier (BBB), it was
suggested that the effects of proteasome inhibition in brain
ischemia may be mediated primarily at the BBB to interfere with
the penetration of inflammatory cells (Phillips et al., 2000). In fact,
proteasome inhibitors may also act directly on leucocytes to
prevent their entry into the brain (Williams et al., 2004).
In addition to the effects in reducing the brain pathology,
MLN519 also improved the neurological outcome after MCAO
(Phillips et al., 2000; Zhang et al., 2001; Williams et al., 2003, 2005).
Furthermore, when combined with tissue plasminogen activator
(tPA), MLN519 reduced the infarct volume and improved the
neurological outcome as determined 1 week after stroke (Zhang
et al., 2001). Similarly, the proteasome inhibitor bortezomib
combined with low doses of tPA showed additional neuroprotec-
tive effects when tested in a model of embolic stroke in rats (Zhang
et al., 2006b, 2010). Single administration of bortezomib within 2–
4 h after injury also showed neuroprotective effects, and the
proteasome inhibitor was proposed to act by promoting eNOS-
dependent vascular protection and to prevent NF-kB-dependent
vascular disruption (Zhang et al., 2006b,c, 2010).
Although bortezomib has been approved by the Food and Drug
Administration for the treatment of multiple myeloma and mantle
cell lymphoma, the clinical use of this proteasome inhibitor is
limited because of severe side effects (Ruschak et al., 2011). A novel
proteasome inhibitor, BSc2118, which is putatively better tolerat-
ed, was shown to provide protection in mice subjected to
intraluminal MCAO, when injected intrastriatally no later than
12 h post-stroke. A single injection of BSc2118 provided long-term
neuroprotection, reduced functional impairment, stabilized the
blood–brain barrier by decreasing MMP9 activity and enhancedangioneurogenesis. The upregulation of the HIF1A transcription
factor is also an important mediator in BSc2118-induced
neuroprotection (Doeppner et al., 2012). Furthermore, BSc2118
treatment increased the levels of erythropoietin, brain-derived
neurotrophic factor and vascular endothelial growth factor,
suggesting that the proteasome inhibitor may provide acute
neuroprotection in addition to enhancing brain remodeling
(Doeppner et al., 2012).
The apparent contradiction between the neuronal death
resulting from proteasome inhibition and the effect of proteasome
inhibitors in brain ischemia may be explained by an effect of
proteasome inhibition in the secondary phase of brain injury and in
neuroinflammation after stroke, which are reduced by these
compounds. Although neurons are sensitive to proteasome
inhibition, they may be able to tolerate relatively long periods
of intracellular accumulation of ubiquitinated proteins, allowing
the control of neuroinflammation with the proteasome inhibitors.
The recent development of small molecule inhibitors of
deubiquitinating enzymes (USP and other classes of DUBs), which
stabilize the polyubiquitin chains bound to their specific targets
and thereby promote their degradation, will allow testing the
effect of upregulating the proteasome activity on ischemia-
induced neuronal damage. From the experimental and clinical
points of view, these molecules will benefit from the specificity of
each one of the USP. A recent study reported the effect of IU1,
which acts as a Usp14 inhibitor, a DUB that acts as a negative
regulator of the 26S proteasome (Lee et al., 2010), on transient focal
cerebral ischemia induced by MCAO. Administration of IU1 1 day
before MCAO significantly reduced the infarct volume, when
determined 4 days after the lesion. In this case the effects of IU1
were correlated with the control of REST protein levels, which is
known to increase in ischemic neurons destined to die (Doeppner
et al., 2013). However, it remains to be determined whether IU1 is
also neuroprotective when administered after the ischemic injury.
The upregulation of protein degradation by the proteasome in the
presence of IU1 may compensate for the toxic effects resulting
from a downregulation of the proteasome activity in brain
ischemia. However, additional studies should be performed to
investigate the cellular and molecular mechanisms of neuropro-
tection by this DUB inhibitor.
5. Conclusions
The available evidence clearly point to a role of excitotoxic
damage in ischemia-induced downregulation of the proteasome
activity, which may contribute to neuronal death. However, at this
point we have a limited understanding of the effect of brain
ischemia on the other components of the UPS, in particular ligases
and deubiquitinases, which should have an impact on the
abundance of their target proteins. The results showing distinct
effects of excitotoxic cell damage on the activity of the proteasome
in the nuclear and cytosolic compartments also suggest that UPS
targets may be differentially affected in brain ischemia depending
on their location in the cell. In particular, alterations in the UPS in
the nuclear compartment may affect the activity of transcription
factors, thereby altering gene expression. Given the role of the UPS
in synaptic regulation, alterations in the proteasome activity may
also lead to changes in the activity of excitatory and inhibitory
synapses. Although proteasome inhibitors have been shown to
provide protection in brain ischemia, alternative strategies,
specifically targeting the molecular mechanisms responsible for
neuroinflammation, are likely to provide better results since
they would avoid exacerbating the problems arising from the
stroke-induced downregulation of the proteasome. The future
development of small molecule inhibitors of deubiquitinating
ubiquitin-specific proteases (USP) (Zhang et al., 2013b) and other
M.V. Caldeira et al. / Progress in Neurobiology 112 (2014) 50–6964deubiquitinating enzymes (Tan et al., 2008) will also allow
modifying in a more specific manner the abundance of protein
targets of the UPS and may prove to be useful as neuroprotective
strategies in brain ischemia. Furthermore, although proteasome
inhibitors and activators have shown neuroprotective effects in
cerebral ischemia the detailed biochemical alterations in the
ubiquitin-modified landscape after ischemia remain to be eluci-
dated.
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